2. • Introduction
• Benefits
• Methods of improving compliance
• Antipsychotic Long Acting Injections (LAI)
• Pharmacology
• Individual Long Acting Antipsychotics
• Advantages & Disadvantages
• Conclusion
3. • Antipsychotic medications can also be administered as long-acting injectable
compounds.
• These drugs differ from short-acting compounds in that they are released slowly over a
period of several weeks and as a result can take days or weeks to achieve therapeutic
serum concentration and weeks to months to achieve steady state.
• Schizophrenia is a major psychiatric disorder, or cluster of disorders, characterized by
psychotic symptoms that alter a person's perception, thoughts, mood and behavior.
• Continuous, long-term treatment to minimize relapse and provide clinical benefit to
patients.
INTRODUCTION
4. • Non-compliance to medication is a major risk factor for relapse and re-hospitalization.
• Non-adherence may be both a cause and consequence of worsening of illness
• Long-acting injectable antipsychotic drugs can help to:
Improve compliance
Reduce relapse
Lower hospitalization rates
5. Benefits
⚫Consistent drug delivery.
⚫Predictable bioavailability.
⚫Eliminates risk of patient deliberately or inadvertently overdosing.
⚫Avoidance of covert non-adherence to antipsychotic drug
⚫Immediate identification of patients who decline their injection or fail
to receive it through forgetfulness
NICE Guidelines for Schizophrenia. 2009.
7. Antipsychotic Long Acting Injections (LAI)
Two groups of LAIs: First generation LAIs and Second-generation LAIs.
•FGA LAI are esters of parent FGA combined with a long chain fatty acid .
Decanoic acid -10 carbon, enthanate -8 , undecylenate -11 , palmitate -16.
• Once esterified FGA becomes fat soluble dissolved in oily base, such as sesame ,
coconut
9. First-generation LAIs
Flupentixol:
◦ Thioxanthine antipsychotic.
◦ LAI is formulated as flupentixol decanoate in a low-viscosity vegetable oil
(fractionated coconut oil).
◦ Peak plasma levels 3–7 days after IM injection
◦ Apparent half-life of 17 days.
◦ Steady-state plasma levels can be expected to be achieved after 2 months or
so of regular dosing.
◦ In practice, plasma levels may show marked variability independent of dose
changes.
9
10. o It is available as brand name
o Inj Fluanxol 20 mg/ml and 40 mg/2ml
o Inj Spenzo 20 mg/ml and 40mg/2ml
o Cost around 100-200 Rs for 20 mg amp and 200-400 Rs for 40 mg amp.
oInitially 20 mg should be given as a test dose. If well tolerated 20-40mg may be
given after 1 wk.
o Maintenance dose of 20-40 mg can be given every 2-4 wks.
o Dose of depot is 8 times of total oral dose
o It has mood elevating property, may worsen agitation.
11. First-generation LAIs
Fluphenazine:
◦ Piperazine phenothiazine compound.
◦ Fluphenazine decanoate is available as an LAI in sesame oil.
◦ Plasma levels peak within 24 h of intramuscular injection
◦ Half-life is approximately 7–14 days.
◦ Plasma levels obtained vary up to 40-fold in patients receiving the same dose.
◦ Smoking significantly reduces plasma fluphenazine levels.
◦ Available in brand name : Inj Prolinate 25mg/ml, 50 mg/2ml (amp)
◦ Cost around 45 – 50 Rs.
11
12. 🞭Pros
🞤2-4wk administration
🞤Generic formulation
🞭Cons
🞤Risk of EPS and tardive dyskinesia
🞤No established loading dose option
⚫THERAPEUTIC ACTIONS
Mechanism not fully understood: antipsychotic drugs block postsynaptic dopamine
receptors in the brain, depress the RAS, including the parts of the brain involved with
wakefulness and emesis; anticholinergic, antihistaminic (H 1), and alpha-adrenergic
blocking activity also may contribute to some of its therapeutic (and adverse) actions.
13. Metabolism: Fluphenazine is extensively metabolized, undergoing "first pass"
metabolism by the liver, and is excreted in both the urine and faeces
Distribution: Crosses placenta; enters breast milk
Excretion: Unchanged in the urine
Indication
Fluphenazine decanoate is indicated in the long-term management of psychotic
disorders including schizophrenia, mania and organic brain syndrome.
It is of particular value in the treatment of chronic schizophrenia and for patients who
are unreliable at taking oral medication.
14. • The drug often alleviates such target symptoms as hallucinations, delusions, confusion
and withdrawal.
• It is not only useful in the hospital milieu but is unparalleled, because of its long
duration of action in the long-term maintenance therapy of chronically psychotic
patients who are amenable to out-patient therapy.
15. First-generation LAIs
Haloperidol:
◦ Butyrophenone
◦ Haloperidol decanoate is a ester of haloperidol and decanoic acid dissolved in
Sesame seed oil.
◦ After intramuscular injection, haloperidol decanoate is gradually released
from muscle tissue and hydrolysed slowly into free haloperidol which enters
the systemic circulation.
◦ Haloperidol decanoate is a potent dopamine antagonist and, therefore, a very
incisive neuroleptic.
◦ Peak plasma levels are seen up to 7 days after intramuscular injection
16. ◦ Plasma half-life is around 3 weeks.
◦ Steady-state plasma levels can be expected to be reached after 2–3 months of regular
dosing.
◦ Variation in plasma levels is smaller than oral haloperidol.
◦It is available as brand name
Inj Senorm LA – 50 mg/ml
Inj Trancodol LA- 50 mg/ml
o It cost around 180-200 Rs per 1 Amp of 50 amp
oWhile switching from oral to depot dose can be calculated as 15-20 times daily oral dose
at every 4 wk interval.
o Maximum dose can be given is 300/4wks.
18. • Metabolism
Metabolised by several routes including the cytochrome P450 enzyme system
(particularly CYP 3A4 or CYP 2D6) and glucoronidation.
• Elimination
After reaching peak plasma concentrations, levels fall with an apparent half-life of
about 3 weeks.
Haloperidol is excreted in the urine (40%) and faeces (60%). About 1% of the dose
is excreted unchanged with the urine.
• Indication
For the maintenance therapy of psychoses, particularly for patients requiring
prolonged parenteral neuroleptic therapy.
19. First-generation LAIs
Perphenazine:
◦ Piperazine phenothiazine
◦ Perphenazine decanoate in sesame oil.
◦ After intramuscular injection at gluteal region, peak plasma levels are
obtained in 1–7 days
◦ Half-life is approximately 2 weeks.
◦ Steady-state levels are obtained after 3 months.
◦ Variations in plasma levels during regular dosing are small.
◦ Plasma levels are directly correlated with dose.
19
20. First-generation LAIs
Pipotiazine:
◦ Piperidine Phenothiazine Antipsychotic.
◦ The Lai Formulation Contains Pipotiazine Palmitate In Coconut Oil.
◦ Provides Peak Plasma Levels After 1–2 Weeks Although No Drug Is Released
For At Least 3 Days.
◦ Plasma Half-life Is Around 2 Weeks
◦ Time To Steady State Is 2 Months.
20
21. First-generation LAIs
Zuclopenthixol:
◦ Thioxanthine compound.
◦ LAI is formulated as the decanoate ester dissolved in thin vegetable oil
(fractionated coconut oil).
◦ Peak plasma levels of zuclopenthixol are achieved a week after injection.
◦ Plasma half-life has been estimated 19 days.
◦ Dose of 200mg/2 weeks of clopixol depot is equivalent to a daily oral dose of
25 mg clopixol.
21
22. Steady-state plasma levels can be expected to be achieved after 2 months or so of
regular dosing.
In practice, plasma levels may show marked variability independent of dose changes.
It is available as inj. Clopixol depot 200mg/ml amp.
Cost around 300 Rs/amp of 200mg.
It can be given as 200-1200 mg at intervals of 2-4 wks.
It is preferred in agitated and aggressive patients.
23. First-generationLA’S
Drug Injection site Test dose
(mg)
Dose range
(mg/week)
Dosing
Interval
(weeks)
Comments
Flupentixol
decanoate
Gluteal or thigh 20 12.5-400 2-4 Maximum licensed
dose is very high
relative to other LAIs
Fluphenazine
decanoate
Gluteal 12.5 6.25-50 2-5 High EPS
Haloperidol
Decanoate
Gluteal 25 12.5-75 4 High EPS
Pipothiazine
palmitate
Gluteal 25 12.5-50 4 ? Lower incidence of
EPS (unproven)
Zuclopenthixol
decanoate
Gluteal or thigh 100 100-600 2-4 ? Slightly higher
efficacy
24. Second-generation LAIs
Risperidone:
◦ First ‘atypical’ drug to be made available as depot
◦ Belongs to benzisoxazole derivative class
◦ Contains risperidone coated in polymer to form microspheres.
◦ Have to be suspended in an aqueous base immediately before use.
◦ Available as Risperdal consta in doses of 25, 37.5 and 50 mg
◦ Cost around 4000-5000 per 25 mg.
◦ Must be stored in fridge.
25. Absorption:
The main release of the drug starts 3 wk after injection, is maintained from 4 to 6 wk, and
subsides by 7 wk. Steady state is reached after 4 injections
Disutribution:
Volume of distribution: 1-2 L/kg.
Risperidone binds to albumin and alpha1-acid glycoprotein.
Plasma protein binding:
For risperidone: 90%
For 9-hydroxyrisperidone: 77%
26. Metabolism
Extensively metabolized in the liver by CYP2D6 to major active metabolite 9-
hydroxyrisperidone. 9-hydroxyrisperidone has similar activity to risperidone.
Elimination
Eliminated in urine (70%) and feces (14%).
The half-life of risperidone plus 9-hydroxyrisperidone is 3 to 6 days.
Contraindications
Hypersensitivity to risperidone or to any components of the product.
27. Indications and Usage
Treatment of schizophrenia; as monotherapy or as adjunctive therapy to lithium or
valproate for the maintenance treatment of bipolar disorder.
Bipolar Mania
25 mg every 2 wk. Some patients may benefit from a higher dose of 37.5 or 50 mg.
Do not make upward dosage adjustments more frequently than every 4 wk.
•Schizophrenia
•25 mg every 2 wk (max 50 mg every 2 wk). Do not make upward dosage
adjustments more frequently than every 4 wk.
28. PROS AND CONS
•Risperidone injection is not suitable for patients with treatment-refractory schizophrenia.
• Peak release is at about 28 days.
•The long-acting injection also seems to be well tolerated: fewer than 10% of patients
experience EPS and fewer than 6% withdrew from a long-term trial because of adverse
effects.
• Doses of 25–50 mg every 2 weeks appear to be as effective as oral doses of 2–6 mg/day.
•Prolactin levels appear to reduce somewhat following a switch from oral to injectable
risperidone.
• Rates of tardive dyskinesia are said to be low
29. Switching
to risperidone long‐acting injection (RLAI)
Start risperidone oral at 2 mg/day and titrate to effective dose.
If tolerated, prescribe equivalent dose of RLAI Continue with oral risperidone for at
least 3 weeks then taper over 1–2weeks.
Be prepared to continue oral risperidone for longer
Use oral risperidone before giving injection to assure good tolerability
Those stabilised on 2 mg/day start on 25 mg/2 weeks
Those on higher doses, start on 37.5 mg/2 weeks and be prepared to
use 50 mg/2 weeks
30. Second-generation LAIs
Paliperidone:
Contains extended release intramuscular extended-release intramuscular
Paliperidone Palmitate
Major active metabolite of risperidone: 9-hydroxyrisperidone
Active paliperidone plasma levels are seen within a day or so, therefore co-
administration of oral paliperidone or risperidone during initiation is not
required
31. • Paliperidone palmitate IM does not require cold storage.
• Prefilled syringes and does not require reconstitution
• No oral supplementation is required on initiation for paliperidone palmitate.
• No test dose is required for paliperidone palmitate (but patients should ideally be
currently stabilised on or have previously responded to oral paliperidone or
risperidone).
• The median time to maximum plasma concentrations is 13 days.
• Treatment with paliperidone palmitate (100 mg eq.) was efficacious and all doses
tested were tolerable.
32. Paliperidone Dose Route
Initiation
Day 1
Day 8 (+/−2 days)∗
150 mg IM Deltoid only
100 mg IM Deltoid only
Maintenance
Every month (+/− 7 days)
thereafter 50–150 mg IM∗∗ Deltoid or gluteal
∗The second initiation dose may be given 2 days before or after day 8 (after the first initiation dose on
day 1).2 Similarly the manufacturer recommends that patients may be given maintenance doses up to
7 days before or after the monthly time point.2 This flexibility should help to minimise the number of
missed doses.
∗∗The maintenance dose is perhaps best judged by consideration of what might be a suitable dose of
oral risperidone and then giving paliperidone palmitate in an equivalent dose IM, intramuscular
34. Olanzapine
• Crystal salt made of Olanzapine & Palmoic acid.
• Each 15 mg of Olanzapine LAI must be dissolved in 0.1 ml of water.
• Max- 3.0 ml or 450 mg Olanzapine
• 3 hr monitoring after giving injection
• Post Injection Syndrome or Post Injection Delirium Syndrome
35. Parameter Olanzapine LA IM
Metabolism Glucuronidation, CYP1A2 and 2D6
Elimination Urine and feces, 7% unchanged
Half-life 30 days
Protein binding 93%
36. ⚫Intramuscular gluteal injection
3 vial strengths (210 mg, 300 mg, 405 mg)
Once every 2 or 4 week injection
24 hour medication stability in vial once reconstituted
⚫Pros
2wk or 4wk dosing options
New second generation antipsychotic in LAI formulation
⚫Cons
Cost
Needle size
Post-injection monitoring
37. Administration
• Olanzapine LA IM should only be administered as a deep intramuscular gluteal
injection using a 19-gauge, 1.5 inch needle (2 Hypodermic Needle-Pro needles with
protection device are included).
• For obese patients a 2-inch, 19-guage or larger needle can be used for administration
(not included).
• Following the needle’s insertion into the muscle, aspiration should take place for
several seconds to ensure no blood is drawn into the syringe.
• If any blood is aspirated, the needle and dose should be discarded and a new dose
prepared.
• Olanzapine LA IM is not to be administered intravenously or subcutaneously.
• Reconstituted olanzapine is a suspension.
38. Dose Vial Strength Diluent to Add
*Final Injection
Volume
150 mg 210 mg 1.3 mL 1 mL
210 mg 210 mg 1.3 mL 1.4 mL
300 mg 300 mg 1.8 mL 2 mL
405 mg 405 mg 2.3 mL 2.7 mL
DOSE RECONSTITION
39. Target Oral
Olanzapine Dose
Olanzapine LA IM Dose
During the 1st 8 Weeks
Olanzapine LA IM
Maintenance Dose After 8
Weeks
10 mg/day
210 mg every 2 weeks or
405 mg every 4 weeks
150 mg every 2 weeks or
300 mg every 4 weeks
15 mg/day 300 mg every 2 weeks
210 mg every 2 weeks or
405 mg every 4 weeks
20 mg/day 300 mg every 2 weeks 300 mg every 2 weeks
40. Post Injection Syndrome or Post Injection Delirium Syndrome:
• Mimics Olanzapine over dosage
Sedation, dizziness, slurred speech, agitation, confusion, ataxia, weakness ,
unconsciousness
• Majority occurs in first hour post-injection, progressing from mild to severe
presentations
• Mechanism: Olanzapine LAI is highly soluble in blood compared to muscle.
• hypothesized that direct or partial injection into vasculature or bleeding around
injection site leading to direct contact of Olanzapine
41. Switching
Direct switching to olanzapine LAI, ideally following an oral trial, is usually possible.
So, when switching from another LAI (but not risperidone) olanzapine oral or LAI can be started on the
day the last LAI was due.
Likewise for switching from oral treatment – a direct switch is possible but prior antipsychotics are
probably best reduced slowly after starting olanzapine (either oral or LAI).
When switching from risperidone RLAI, olanzapine should be started, we suggest, 3–4 weeks after the
last injection was due (e.g. 5–6 weeks after the last injection).
42. Aripiprazole LAI
It is an extended-releaseinjectablesuspension available in 400 mg or 300 mg strength vials.
its monohydratepolymorphicform
Mechanism of Action
Atypical antipsychotic; partial agonist at dopamine D2 and serotonin type 1 (5-HT1A)
receptors; antagonist at serotonin type 2 (5-HT2A) receptor; also has alpha-blockingactivity
Absorption
Bioavailability:87% (tablet);100% (IM)
Peak plasma time: 1-3 hr (IR); 5-7 hr (ER); 3-5 hr (tablet)
43. Distribution
Protein bound: 99%
Metabolism
Metabolized by CYP2D6 and CYP3A4
Metabolites: Dehydroaripiprazole (40%)
Elimination
Half-life: 75 hr (parent drug); 94 hr (metabolite); 30-47 days (IM); 146 hr (poor
metabolizers)
Excretion: Feces (55%), urine (25%)
44. Schizophrenia
🞭10-15 mg/day PO initially; may be increased to 30 mg/day PO after 2 weeks
Maintenance with once-monthly IM injection
🞭Abilify Maintena: 400 mg IM once monthly; continue treatment with aripiprazole PO (10-20
mg/day) or other oral antipsychotic for 14 consecutive days following first injection
🞭Only to be administered by deep IM injection into gluteal muscle
🞭Establish tolerability with oral aripiprazole prior to initiating if patient has never taken
aripiprazole
🞭Administer monthly dose no sooner than 26 days after previous injection
🞭Consider dose reduction to 300 mg/month if adverse reaction occurs
45. Bipolar Mania
Acute and maintenance treatment of manic or mixed episodes associated with
bipolar I disorder, either as monotherapy or as adjunct to lithium or valproate
Monotherapy: 15 mg/day PO initially; may be increased gradually; not to exceed
30 mg/day
Adjunct to lithium or valproate: 10-15 mg/day PO initially; recommended daily
dose is 15 mg/day; may be gradually increased; not to exceed 30 mg/day
Continue stabilization dose for up to 6 weeks; treatment >6 weeks not studied
46. Switching
Switching to aripiprazole LAI
Oral antipsychotics Cross taper antipsychotic with oral aripiprazole* over 2 weeks.
Start LAI, continue aripiprazole oral for 2 weeks then stop
Depot antipsychotics
(not risperidone LAI)
Start oral aripiprazole* on day last depot injection was due. Start
aripiprazole LAI after 2 weeks then stop oral aripiprazole 2 weeks later
Risperidone LAI Start oral aripiprazole* 5–6 weeks** after the last risperidone injection.
Start aripiprazole LAI 2 weeks later; discontinue oral aripiprazole
2 weeks after that
47. Iloperidone
Iloperidone is an atypical antipsychotic that recently received marketing approval
from the Food and Drug Administration for the acute treatment of schizophrenia.
Iloperidone is a pure antagonist and the first antipsychotic to have
pharmacogenomic studies indicate predictive response based on six identified
polymorphisms.
Iloperidone has been studied for nearly 20 years. In May 2009, the Food and Drug
Administration approved the marketing of iloperidone for the acute treatment of
schizophrenia in adults.
48. The three phases of the study included an open-label predepot phase, in which all patients
with schizophrenia received 21 days of oral iloperidone (target dosage, ≤24 mg daily).
In the second phase, patients received single intramuscular injections of iloperidone (12–
750 mg) or placebo for 28-day cycles.
In the final phase, patients received oral iloperidone for 364 days.
Iloperidone demonstrated sustained release over 28 days, with the depot injections of 360
and 750 mg having comparable AUC values to oral iloperidone 12 and 24 mg/day,
respectively.
Moreover, the tolerability of the depot formulation was similar to that of the oral tablets,
regardless of patient age, sex, or weight.
49. Conclusion
Iloperidone may be a viable and safe option for the treatment of schizophrenia
in adult patients, especially for patients who cannot tolerate other antipsychotic
agents.
